These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16685451)

  • 1. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
    Keller G; Schally AV; Nagy A; Baker B; Halmos G; Engel JB
    Int J Oncol; 2006 Jun; 28(6):1507-13. PubMed ID: 16685451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 can overcome chemoresistance in experimental renal cell carcinomas.
    Keller G; Schally AV; Nagy A; Halmos G; Baker B; Engel JB
    Cancer; 2005 Nov; 104(10):2266-74. PubMed ID: 16211544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human malignant melanomas express receptors for luteinizing hormone releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone releasing hormone analogue.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Westphal G; Halmos G; Engel JB
    Cancer Res; 2005 Jul; 65(13):5857-63. PubMed ID: 15994963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of U-87 MG human glioblastomas in nude mice after treatment with a cytotoxic somatostatin analog AN-238.
    Kiaris H; Schally AV; Nagy A; Sun B; Szepeshazi K; Halmos G
    Clin Cancer Res; 2000 Feb; 6(2):709-17. PubMed ID: 10690557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.
    Szereday Z; Schally AV; Szepeshazi K; Bajo AM; Hebert F; Halmos G; Nagy A
    Int J Oncol; 2003 May; 22(5):1141-6. PubMed ID: 12684683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses.
    Koppan M; Nagy A; Schally AV; Arencibia JM; Plonowski A; Halmos G
    Cancer Res; 1998 Sep; 58(18):4132-7. PubMed ID: 9751625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN-238.
    Plonowski A; Schally AV; Nagy A; Kiaris H; Hebert F; Halmos G
    Cancer Res; 2000 Jun; 60(11):2996-3001. PubMed ID: 10850448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
    Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
    Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: low induction of multidrug resistance proteins.
    Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
    Eur J Cancer; 2005 Aug; 41(12):1824-30. PubMed ID: 16051478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
    Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of experimental DU-145 prostate cancers with targeted cytotoxic somatostatin analog AN-238.
    Plonowski A; Schally AV; Nagy A; Sun B; Halmos G
    Int J Oncol; 2002 Feb; 20(2):397-402. PubMed ID: 11788908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
    Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
    Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human multi-drug resistant hepatocellular carcinoma induced in nude mice by B-ultrasonographically-directed orthotopic implantation: a new experimental model.
    Ding L; Chen XP; Zhang ZW; Jing K; Zhang WG
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):393-8. PubMed ID: 17690036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.
    Engel JB; Schally AV; Halmos G; Baker B; Nagy A; Keller G
    Cancer; 2005 Sep; 104(6):1312-21. PubMed ID: 16047355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent induction of apoptosis in human hepatoma cell lines by targeted cytotoxic somatostatin analogue AN-238.
    Lasfer M; Vadrot N; Schally AV; Nagy A; Halmos G; Pessayre D; Feldmann G; Reyl-Desmars FJ
    J Hepatol; 2005 Feb; 42(2):230-7. PubMed ID: 15664249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel-octreotide conjugates in tumor growth inhibition of A549 human non-small cell lung cancer xenografted into nude mice.
    Shen H; Hu D; Du J; Wang X; Liu Y; Wang Y; Wei JM; Ma D; Wang P; Li L
    Eur J Pharmacol; 2008 Dec; 601(1-3):23-9. PubMed ID: 18983839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
    Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G
    Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition.
    Seitz S; Schally AV; Treszl A; Papadia A; Rick F; Szalontay L; Szepeshazi K; Ortmann O; Halmos G; Hohla F; Buchholz S
    Anticancer Drugs; 2009 Aug; 20(7):553-8. PubMed ID: 19491659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.